Value Assessments Should Include All the Outcomes That Matter to Patients and Families

When it comes to assessing the value of medicines, conventional cost-effectiveness analysis (CEA) methods typically only account for the value of quality-adjusted life years (QALYs) and health care costs and miss important elements of value that matter to patients and society. The outcomes that matter to patients should matter to everyone.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.